Most Read Articles
11 Apr 2018
Survivors of Hodgkin’s lymphoma are at greater risk of developing subsequent malignant neoplasm (SMN) and cardiovascular disease (CVD), according to a study.
15 Jul 2019
New drug applications approved by US FDA as of 01 - 15 July 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date. 

Statins safe, effective in children with familial hypercholesterolaemia

10 Jul 2019
Statin, a blood cholesterol-lowering medicine, reduces sharply in blood cholesterol levels among ACS patients.

Statin therapy is safe and effective in the immediate term in children with familial hypercholesterolaemia, a recent study has found.

Researchers evaluated a prospective cohort of 131 children or adolescents (median age, 10.0 years; 51.1 percent male) who were given statins for familial hypercholesterolaemia. Efficacy was assessed according to the proportion of participants who achieved low-density lipoprotein cholesterol (LDL-C) levels <160 mg/dL. Tolerance was measured according to the occurrence of clinical or laboratory side effects.

Over a median treatment duration of 48 months, median LDL-C levels dropped from 209 mg/dL at baseline to 142 mg/dL. The corresponding percentage difference of –32.0 percent was statistically significant (p<0.0001). More than half (67.4 percent) of the participants achieved the therapeutic LDL-C goal.

Similar effects were observed for other lipid biomarkers. Total cholesterol, for instance, dropped by 24.4 percent (p<0.0001) over the study period, going from 283 mg/dL at baseline to 214 mg/dL at the final follow-up. The same was true for high-density lipoprotein cholesterol (58 to 54.5 mg/dL; percentage difference, –6.0 percent; p=0.0025).

Statin therapy was also acceptably safe, being well tolerated by 81.6 percent (n=107) of the participants. Side effects were reported in 19 patients, and none resulted in permanent discontinuation. However, seven patients had to be switched to another class of statin, none of which resulted in the recurrence of side effects.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
11 Apr 2018
Survivors of Hodgkin’s lymphoma are at greater risk of developing subsequent malignant neoplasm (SMN) and cardiovascular disease (CVD), according to a study.
15 Jul 2019
New drug applications approved by US FDA as of 01 - 15 July 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.